The Future of Drug Trials - Interview

Posted:
29
September 2006

BBC journalist Graham Easton investigates the future of drug trials following the events of trial TGN1412.The BBC interviewer talks to Professor Gordon Duff (Commission on Human Medicines), Professor Andre Mclean (Imperial College London), Dr Jörg Täubel (Richmond Pharmacology), Professor Terry Hamblin (University of Southampton), Dr Ganesh Suntharalingam (Northwick Park Hospital), Professor Deborah Saltman (BioMedical Central), Dr Elaine Godfrey (MHRA), and Dr Mark Lewis (Strategic Health Authority), to get their opinion leading analysis of the event and the future of drug trials, covering:

  • What can be learnt and changed from the incident?
  • Should all first in man trials be conducted in a Hospital setting?
  • Regulatory issues

Click here to read the transcript

Latest news

Upcoming Event

EUFEMED, 3rd Annual Conference, 28-30 April 2021

28-30 April 2021
Dr Jorg Taubel will co-chair a session on day one, which explores how technology has reduced the risks of pandemic effects on Phase I and II trial performance.
View event

Making gains in drug development

September 2, 2021
Keith Berelowitz outlines the innovations in the design and delivery of clinical trials
Read more

Inclisirin hailed as a 'gamechanger' gains approval for NHS patients

September 2, 2021
This novel therapeutic drug has potential to impact millions at risk of heart attack and stroke.
Read more

Richmond Pharmacology listed in the Alantra Pharma Fast 50

July 13, 2021
Richmond has been included in a top 50 list of the UK’s fastest-growing, privately-owned pharmaceutical businesses. 
Read more